Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy
نویسندگان
چکیده
منابع مشابه
Alterations in serum levels of trace element in patients with breast cancer before and after chemotherapy
Background: Breast cancer is the most common serious disease around the world. The trace elements have a vital role in the metabolism and chemotherapy may change the level of metal ions. Due to the ambiguity of the existence in this regard, the study examined the trace element serum levels in women with breast cancer before and after chemotherapy . Methods: Sixty patients were studied undergoi...
متن کاملAssociation Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients
PURPOSE To retrospectively investigate the quantitative background parenchymal enhancement (BPE) of the contralateral normal breast in patients with unilateral invasive breast cancer throughout multiple monitoring points of neoadjuvant chemotherapy (NAC) and to further determine whether BPE is associated with tumor response, especially at the early stage of NAC. MATERIALS AND METHODS A total ...
متن کاملTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
BACKGROUND Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. METHODS This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observ...
متن کاملChanges in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study
Background & Objective: Premalignant lesions of cervix have increased dramatically in recent years. Early diagnosis and management of abnormalitie...
متن کاملNeoadjuvant Therapy for HER2-positive Breast Cancer.
In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and - depending on the tumor biology - endocrine adjuvant therapy, and ultimately follow up. 10-year survival rates...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicine
سال: 2018
ISSN: 0025-7974,1536-5964
DOI: 10.1097/md.0000000000012965